Influence of Pre-Season Antibodies against Influenza Virus on Risk of Influenza Infection among Health Care Personnel.

BACKGROUND The association of hemagglutination inhibition (HAI) antibodies with protection from influenza among healthcare personnel (HCP) with occupational exposure to influenza viruses has not been well-described. METHODS The Respiratory Protection Effectiveness Clinical Trial was a cluster-randomized, multi-site study that compared medical masks to N95 respirators in preventing viral respiratory infections among HCP in outpatient healthcare settings for 5,180 participant-seasons. Serum HAI antibody titers before each influenza season and influenza virus infection confirmed by polymerase chain reaction were studied over four study years. RESULTS In univariate models, the risk of influenza A(H3N2) and B virus infections was associated with HAI titers to each virus, study year, and site. HAI titers were strongly associated with vaccination. Within multivariate models, each log base 2 increase in titer was associated with 15%, 26% and 33-35% reductions in the hazard of influenza A(H3N2), A(H1N1) and B infections, respectively. Best models included pre-season antibody titers and study year, but not other variables. CONCLUSIONS HAI titers were associated with protection from influenza among HCP with routine exposure to patients with respiratory illness and influenza season contributed to risk. HCP can be reassured about receiving influenza vaccination to stimulate immunity.

[1]  Alexandria C Brown,et al.  Take-home kits to detect respiratory viruses among healthcare personnel: Lessons learned from a cluster randomized clinical trial , 2021, American Journal of Infection Control.

[2]  Alexandria C Brown,et al.  N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. , 2019, JAMA.

[3]  B. Cowling,et al.  Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis , 2018, Journal of Infectious Diseases.

[4]  H. Maecker,et al.  Diminished B-Cell Response After Repeat Influenza Vaccination , 2018, The Journal of infectious diseases.

[5]  M. Eichelberger,et al.  Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population , 2018, bioRxiv.

[6]  B. Cowling,et al.  Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Cummings,et al.  Timescales of influenza A/H3N2 antibody dynamics , 2017, bioRxiv.

[8]  Bhupal Singh.  Influenza , 1916, Nature Reviews Disease Primers.

[9]  L. Hall,et al.  A systematic review and meta-analysis of the direct epidemiological and economic effects of seasonal influenza vaccination on healthcare workers , 2018, PloS one.

[10]  Alexandria C Brown,et al.  Protecting Healthcare Personnel in Outpatient Settings: The Influence of Mandatory Versus Nonmandatory Influenza Vaccination Policies on Workplace Absenteeism During Multiple Respiratory Virus Seasons , 2018, Infection Control & Hospital Epidemiology.

[11]  E. Harris,et al.  Association between Haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015. , 2017, Vaccine.

[12]  C. Chiu,et al.  Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time , 2017, Scientific Reports.

[13]  D. Cummings,et al.  The Respiratory Protection Effectiveness Clinical Trial (ResPECT): a cluster-randomized comparison of respirator and medical mask effectiveness against respiratory infections in healthcare personnel , 2016, BMC Infectious Diseases.

[14]  J. Powers,et al.  Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model , 2016, mBio.

[15]  J. Katz,et al.  Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. , 2016, Vaccine.

[16]  C. Diazgranados,et al.  Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial , 2016, Clinical and Vaccine Immunology.

[17]  Lynnette Brammer,et al.  Influenza Activity — United States, 2014–15 Season and Composition of the 2015–16 Influenza Vaccine , 2015, MMWR. Morbidity and mortality weekly report.

[18]  C. Legrand,et al.  Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease , 2015, Open forum infectious diseases.

[19]  D. Cummings,et al.  Triggering Interventions for Influenza: The ALERT Algorithm , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  T. R. Peters,et al.  Influenza vaccine in the red zone defense: a game-day player. , 2014, The Journal of infectious diseases.

[21]  B. Cowling,et al.  Association between antibody titers and protection against influenza virus infection within households. , 2014, The Journal of infectious diseases.

[22]  Lynnette Brammer,et al.  Influenza Activity — United States, 2013–14 Season and Composition of the 2014–15 Influenza Vaccines , 2014, MMWR. Morbidity and mortality weekly report.

[23]  Lynnette Brammer,et al.  Influenza Activity — United States, 2012–13 Season and Composition of the 2013–14 Influenza Vaccine , 2013, MMWR. Morbidity and mortality weekly report.

[24]  R. Rothman,et al.  Clinical Accuracy of a PLEX-ID Flu Device for Simultaneous Detection and Identification of Influenza Viruses A and B , 2012, Journal of Clinical Microbiology.

[25]  E. Sacadura-Leite,et al.  Antibody response to the influenza vaccine in healthcare workers. , 2012, Vaccine.

[26]  Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. , 2012, MMWR. Morbidity and mortality weekly report.

[27]  A. Monto,et al.  Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. , 2011, The Journal of infectious diseases.

[28]  A. Ng,et al.  Effectiveness of seasonal influenza vaccination in healthcare workers: a systematic review. , 2011, The Journal of hospital infection.

[29]  R. Rappuoli,et al.  Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children , 2011, The Pediatric infectious disease journal.

[30]  A. Falsey,et al.  Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. , 2009, The Journal of infectious diseases.

[31]  R. Couch.  Seasonal inactivated influenza virus vaccines. , 2008, Vaccine.

[32]  J. Stoddard,et al.  Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine , 2004, Expert review of vaccines.

[33]  P. Peduzzi,et al.  Immunity to influenza in older adults with chronic obstructive pulmonary disease. , 2004, The Journal of infectious diseases.

[34]  A. Osterhaus,et al.  Haemagglutination-inhibiting antibody to influenza virus. , 2003, Developments in biologicals.